ReviewChemistry & biodiversity2026
From Marine Peptides to Oncology: The Therapeutic Potential of Conotoxins in Cancer Treatment.
Review in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Marine-derived conotoxins, developed selective cancer therapy lead compounds that cone snails secrete as potent peptide toxins able to alter ion channels and disrupt cancer cell communication processes. The research explores the mechanism by which conotoxins trigger programmed cell death, combat drug resistance, and restrict cancer cell proliferation at the molecular level. Their clinical application is restricted by their instability, along with rapid degradation and adverse pharmacological activity. The therapeutic value of peptides is furthered by backbone cyclization and PEGylation strategies, which increase bioavailability coupled with improvement in metabolic stability. Conotoxins offer a new kind of therapy since they are capable of specifically curing aberrant ion movements characterized in cancer cells, which result in resistance to therapy. Bioactive peptides have a promising future as cancer therapy revolutionizers when administered via nanocarrier systems and maximized by means of chemical refinement techniques.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.